The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| FSNU.F | +47.77% | +61.32% | +10.02% | -68% |
| S&P | +17.53% | +93.66% | +14.13% | +422% |
Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment caters to individuals with renal diseases. The Fresenius Kabi segment specializes in lifesaving medicines and technologies. The Fresenius Helios offers expertise in inpatient and outpatient care as well as in telemedicine. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The company was founded by Eduard Fresenius on October 1, 1912 and is headquartered in Bad Homburg, Germany.
No news articles found for Fresenius SE & Co.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $6.33B | 7.7% |
| Gross Profit | $1.65B | 25.6% |
| Gross Margin | 26.12% | 3.7% |
| Market Cap | $28.33B | 61.7% |
| Market Cap / Employee | $0.16M | 61.3% |
| Employees | 176.2K | 0.2% |
| Net Income | $391.34M | 3129.3% |
| EBITDA | $932.42M | 47.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.44B | 21.2% |
| Accounts Receivable | $4.46B | 8.1% |
| Inventory | 3K | 6.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.44B | 0.7% |
| Short Term Debt | $2.65B | 23.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.11% | 2.3% |
| Return On Invested Capital | 3.79% | 0.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $283.05M | -59.0% |
| Operating Free Cash Flow | $615.99M | -30.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 38.04 | 52.80 | 22.95 | - | |
| Price to Book | 1.03 | 0.88 | 1.14 | 1.35 | 61.98% |
| Price to Sales | 0.89 | 0.82 | 1.01 | 1.17 | 67.66% |
| Price to Tangible Book Value | 11.82 | 9.64 | 10.96 | 12.15 | 34.79% |
| Price to Free Cash Flow TTM | 8.89 | 11.79 | 14.71 | 41.23 | 720.15% |
| Enterprise Value to EBITDA | 42.51 | 36.14 | 39.30 | 45.73 | -6.05% |
| Free Cash Flow Yield | 11.2% | 8.5% | 6.8% | 2.4% | -87.81% |
| Return on Equity | 3.1% | 5.5% | 6.2% | 7.1% | 194.02% |
| Total Debt | $14.86B | $14.06B | $14.72B | $15.09B | 3.99% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
